Cantor Fitzgerald Forecasts Zai Lab FY2025 Earnings

Zai Lab Limited (NASDAQ:ZLAB) – Cantor Fitzgerald issued their FY2025 earnings per share estimates for Zai Lab in a research note issued on Tuesday, January 21st. Cantor Fitzgerald analyst L. Chen expects that the company will post earnings per share of ($1.38) for the year. Cantor Fitzgerald has a “Overweight” rating on the stock. The consensus estimate for Zai Lab’s current full-year earnings is ($2.58) per share.

Separately, JPMorgan Chase & Co. upped their price target on Zai Lab from $38.00 to $44.00 and gave the stock an “overweight” rating in a research note on Monday, October 21st.

Zai Lab Price Performance

ZLAB stock opened at $26.00 on Wednesday. Zai Lab has a 1 year low of $13.48 and a 1 year high of $36.60. The firm has a 50-day moving average of $26.71 and a 200 day moving average of $23.68.

Institutional Investors Weigh In On Zai Lab

Several large investors have recently bought and sold shares of ZLAB. Y Intercept Hong Kong Ltd bought a new stake in shares of Zai Lab in the third quarter worth approximately $225,000. China Universal Asset Management Co. Ltd. raised its stake in Zai Lab by 58.1% during the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 9,559 shares of the company’s stock valued at $231,000 after buying an additional 3,514 shares during the last quarter. Daiwa Securities Group Inc. lifted its holdings in shares of Zai Lab by 4,851.8% during the 3rd quarter. Daiwa Securities Group Inc. now owns 9,557 shares of the company’s stock valued at $231,000 after buying an additional 9,364 shares during the period. RBF Capital LLC purchased a new position in shares of Zai Lab in the 3rd quarter worth $241,000. Finally, Dimensional Fund Advisors LP bought a new stake in shares of Zai Lab in the second quarter worth $270,000. 41.65% of the stock is currently owned by institutional investors.

Insider Buying and Selling at Zai Lab

In other Zai Lab news, insider Rafael Amado sold 7,583 shares of Zai Lab stock in a transaction on Tuesday, December 31st. The stock was sold at an average price of $26.28, for a total value of $199,281.24. Following the completion of the sale, the insider now owns 33,834 shares of the company’s stock, valued at approximately $889,157.52. This trade represents a 18.31 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. 13.88% of the stock is owned by company insiders.

Zai Lab Company Profile

Zai Lab Limited develops and commercializes therapies to treat oncology, autoimmune disorders, infectious diseases, and neuroscience. Its commercial products include Zejula, an orally administered poly polymerase 1/2 inhibitor; Optune, a cancer therapy that uses electric fields tuned to specific frequencies to kill tumor cells; NUZYRA for acute bacterial skin and skin structure infections, and community acquired bacterial pneumonia; Qinlock to treat gastrointestinal stromal tumors, and VYVGART, a human IgG1 antibody fragment for myesthenia gravis.